Introduction to Chemo-Induced Myelosuppression and COSELA™
COSELA™ (trilaciclib) Indication, Mechanism of Action, and Clinical Overview
Safety, Dosing, & Administration of COSELA™ (trilaciclib)
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
To report suspected adverse reactions, contact G1 Therapeutics at 1-800-790-G1TX or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This information is not comprehensive. Please see the full Prescribing Information.
Please see full Prescribing Information.